CancerTYPE ID Study Underscores Value of Knowing Tissue of Origin Amid Tissue-Agnostic Approvals
The use of BRAF inhibitors in patients with BRAF V600E mutations without identification of site of origin in CUP patients can lead to inappropriate therapy.
United States Tafinlar Mekinist Kai Treuner Anthony Greco American Society Of Clinical Oncology Drug Administration
Source: precisiononcologynews.com